{"title":"[预防造影剂肾病的实用方案的有效性:改善造影剂肾病的预防]。","authors":"Yoshito Yamaguchi, Masashi Morita, Akira Mega, Ryota Haga, Ikue Nagayama, Yu Yamanouchi, Tatsufumi Oka, Katsuyuki Nagatoya, Atsushi Yamauchi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In Japan, \"Guidelines for iodinated contrast in a patient with chronic kidney disease (CKD) 2012\" was published, but preventive protocols for specific contrast-induced nephropathy (CIN) have not been specified. Therefore, we developed a CIN preventive protocol, and validated its operation and renal protective effect.</p><p><strong>Methods: </strong>In a retrospective cohort study, we determined eGFR within 3 months before contrast-enhanced computed tomography (CECT). We evaluated CKD stage 3b - 4 adult patients (eGFR 15 - 45 mL/min/1.73m2) who underwent CECT. We observed changes in renal function over 9 months and compared the changes between the pre-protocol group, which received CIN preventive measures from clinicians, and the post-protocol group, which received 500 mL 0.9% saline intravenously over 4 hours or drank 2,000 mL water over 36 hours.</p><p><strong>Results: </strong>The numbers of CT and CECT patients after validation of the protocol were 5,450 and 2,037, respectively. Among the CECT patients, 310 (15.2%) and 77(3.8%)had eGFRs < 60 and 45 mL/min/1.73 m2, respectively. Among the CECT patients whose eGFRs were < 60 mL/min/1.73 m2, 74.5% were 70 years or older. Tumor scanning accounted for 77% of all CECT cases. The number of CECT patients after 3 months did not significantly differ between the groups (2,189 vs 2,037). The percentage of patients with CKD stage G3b - 4 showed no significant differences (3.3% vs 3.7%, p = 0.89). The proportion of patients whose eGFR did not deteriorate at 3, 6 and 9 months was significantly higher in the post-protocol group than in the pre-protocol group (p < 0.001), and the protocol was the only independently-significant predictor.</p><p><strong>Conclusions: </strong>Our protocol prevented CIN and provided a renal protective effect without reducing the number of CECT patients.</p>","PeriodicalId":19721,"journal":{"name":"Nihon Jinzo Gakkai shi","volume":"58 4","pages":"587-95"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Effectiveness of a practical protocol for the prevention of contrast-induced nephropathy: improved prevention of contrast-induced nephropathy].\",\"authors\":\"Yoshito Yamaguchi, Masashi Morita, Akira Mega, Ryota Haga, Ikue Nagayama, Yu Yamanouchi, Tatsufumi Oka, Katsuyuki Nagatoya, Atsushi Yamauchi\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In Japan, \\\"Guidelines for iodinated contrast in a patient with chronic kidney disease (CKD) 2012\\\" was published, but preventive protocols for specific contrast-induced nephropathy (CIN) have not been specified. Therefore, we developed a CIN preventive protocol, and validated its operation and renal protective effect.</p><p><strong>Methods: </strong>In a retrospective cohort study, we determined eGFR within 3 months before contrast-enhanced computed tomography (CECT). We evaluated CKD stage 3b - 4 adult patients (eGFR 15 - 45 mL/min/1.73m2) who underwent CECT. We observed changes in renal function over 9 months and compared the changes between the pre-protocol group, which received CIN preventive measures from clinicians, and the post-protocol group, which received 500 mL 0.9% saline intravenously over 4 hours or drank 2,000 mL water over 36 hours.</p><p><strong>Results: </strong>The numbers of CT and CECT patients after validation of the protocol were 5,450 and 2,037, respectively. Among the CECT patients, 310 (15.2%) and 77(3.8%)had eGFRs < 60 and 45 mL/min/1.73 m2, respectively. Among the CECT patients whose eGFRs were < 60 mL/min/1.73 m2, 74.5% were 70 years or older. Tumor scanning accounted for 77% of all CECT cases. The number of CECT patients after 3 months did not significantly differ between the groups (2,189 vs 2,037). The percentage of patients with CKD stage G3b - 4 showed no significant differences (3.3% vs 3.7%, p = 0.89). The proportion of patients whose eGFR did not deteriorate at 3, 6 and 9 months was significantly higher in the post-protocol group than in the pre-protocol group (p < 0.001), and the protocol was the only independently-significant predictor.</p><p><strong>Conclusions: </strong>Our protocol prevented CIN and provided a renal protective effect without reducing the number of CECT patients.</p>\",\"PeriodicalId\":19721,\"journal\":{\"name\":\"Nihon Jinzo Gakkai shi\",\"volume\":\"58 4\",\"pages\":\"587-95\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nihon Jinzo Gakkai shi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Jinzo Gakkai shi","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:在日本,“2012年慢性肾脏疾病(CKD)患者碘造影剂指南”已经发表,但特异性造影剂肾病(CIN)的预防方案尚未明确。因此,我们制定了CIN的预防方案,并验证了其操作和肾脏保护作用。方法:在一项回顾性队列研究中,我们在对比增强计算机断层扫描(CECT)前3个月内测定了eGFR。我们评估了接受CECT的CKD 3b - 4期成人患者(eGFR 15 - 45 mL/min/1.73m2)。我们观察了9个月的肾功能变化,并比较了方案前组和方案后组之间的变化,方案前组接受临床医生的CIN预防措施,方案后组在4小时内静脉注射500 mL 0.9%生理盐水或在36小时内饮用2000 mL水。结果:方案验证后CT和CECT患者分别为5450例和2037例。在CECT患者中,egfr < 60和45 mL/min/1.73 m2的分别为310例(15.2%)和77例(3.8%)。egfr < 60 mL/min/1.73 m2的CECT患者中,年龄≥70岁的占74.5%。肿瘤扫描占所有CECT病例的77%。3个月后CECT患者的数量在两组之间没有显著差异(2189对2037)。CKD分期G3b - 4的患者比例无显著差异(3.3% vs 3.7%, p = 0.89)。方案后组eGFR在3、6和9个月时未恶化的患者比例显著高于方案前组(p < 0.001),方案是唯一具有独立意义的预测因素。结论:我们的方案在不减少CECT患者数量的情况下预防了CIN并提供了肾脏保护作用。
[Effectiveness of a practical protocol for the prevention of contrast-induced nephropathy: improved prevention of contrast-induced nephropathy].
Background: In Japan, "Guidelines for iodinated contrast in a patient with chronic kidney disease (CKD) 2012" was published, but preventive protocols for specific contrast-induced nephropathy (CIN) have not been specified. Therefore, we developed a CIN preventive protocol, and validated its operation and renal protective effect.
Methods: In a retrospective cohort study, we determined eGFR within 3 months before contrast-enhanced computed tomography (CECT). We evaluated CKD stage 3b - 4 adult patients (eGFR 15 - 45 mL/min/1.73m2) who underwent CECT. We observed changes in renal function over 9 months and compared the changes between the pre-protocol group, which received CIN preventive measures from clinicians, and the post-protocol group, which received 500 mL 0.9% saline intravenously over 4 hours or drank 2,000 mL water over 36 hours.
Results: The numbers of CT and CECT patients after validation of the protocol were 5,450 and 2,037, respectively. Among the CECT patients, 310 (15.2%) and 77(3.8%)had eGFRs < 60 and 45 mL/min/1.73 m2, respectively. Among the CECT patients whose eGFRs were < 60 mL/min/1.73 m2, 74.5% were 70 years or older. Tumor scanning accounted for 77% of all CECT cases. The number of CECT patients after 3 months did not significantly differ between the groups (2,189 vs 2,037). The percentage of patients with CKD stage G3b - 4 showed no significant differences (3.3% vs 3.7%, p = 0.89). The proportion of patients whose eGFR did not deteriorate at 3, 6 and 9 months was significantly higher in the post-protocol group than in the pre-protocol group (p < 0.001), and the protocol was the only independently-significant predictor.
Conclusions: Our protocol prevented CIN and provided a renal protective effect without reducing the number of CECT patients.